Introduction The Flow Re-Direction Endoluminal Device (FRED; MicroVention) and its version dedicated for smaller vasculature FRED Jr. (MicroVention) belong to the worldwide most frequently used FD. Several studies showed a good efficacy of the FRED and FRED Jr. with a good safety profile in the short and mid-term. However, to date there are no targeted long term-follow-up data covering more than five years for these devices.
Aim of Study This study focuses on long-term outcomes after aneurysm treatment with either the FRED or the FRED Jr. to investigate the durability of treatment effect and long-term complications.
Methods Patients treated with either FRED or FRED Jr. between 2013 and 2017 at our institution, and thus a possibility for ≥5 years of follow-up, were retrospectively analysed. Aneurysm occlusion rates, recurrence rates, modified Rankin Scale score shifts to baseline, and delayed complications were assessed.
Results 68 patients with 84 aneurysms had long-term follow-up with a mean duration of 57.3 months. 44 patients harbouring 52 aneurysms had a follow-up ≥5 years with a mean follow-up period of 69.2 months. Complete occlusion was reached in 77.4% at two years and increased to 84.9% when the latest available imaging result was considered. After the two-years threshold, there were three reported symptomatic non-serious adverse events.
Conclusion This long-term follow-up study demonstrates that the FRED and FRED Jr. are safe and effective for the treatment of cerebral aneurysms in the long-term, with high rates of complete occlusion and low rates of delayed adverse events.
Disclosure of Interest Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.